News

April 3, 2017 - AB2 Bio Ltd’s Tadekinig alfa therapy receives Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for the treatment of monogenic, Interleukin-18 (IL-18) associated autoinflammatory conditions with ongoing systemic inflammation. In addition, AB2 Bio Ltd receives Orphan Drug Designation from the FDA for the treatment of Haemophagocytic Lymphohistiocytosis (HLH).

• Breakthrough Therapy Designation (BTD) recognises the major potential therapeutic benefits of Tadekinig alfa (IL-18BP) in the treatment of severe and potentially fatal autoinflammatory conditions
• FDA BTD and ODD status supports the accelerated development of Tadekinig alfa

For the press release, please click on the following:

English / Français / Deutsch

November 29, 2016 - AB2 Bio Ltd receives Orphan Drug Designation from the European Medicines Agency for the treatment of Haemophagocytic Lymphohistiocytosis (HLH)

• Important regulatory milestone recognizing the potential therapeutic benefits of IL-18BP in treating HLH, a broad family of severe autoinflammatory diseases with high unmet medical need
• EMA ODD status supports accelerated Phase III development of Tadekinig alfa (IL-18BP)

For the press release, please click on the following:

English / Français / Deutsch

January 11, 2016 - AB2 Bio Ltd raises CHF 21 million (USD 21 million) in Series B financing round

• Over CHF 41 million raised since the foundation of the company
• Strong commitment from current and new investors
• Company funded through Phase II trial in Adult onset Still’s disease and a pivotal Phase III trial in a rare genetic disease

For the press release, please click on the following:

English / Français / Deutsch

November 9, 2015 - AB2 Bio Ltd achieves a medical breakthrough in the treatment of systemic inflammation

• Drug candidate effective in treating a baby girl carrying a newly identified, potentially fatal, genetic mutation causing severe systemic inflammation
• Case report to be presented at the Annual Meeting of the American College of Rheumatology (ACR)

For the press release, please click on the following:

English / Français / Deutsch


Media Contacts:

Stefan Mathys
Partner, IRF Communications AG
T +41 43 244 81 49
stefan.mathys@irfcom.ch